Lyell Immunopharma, Inc. — Director's Dealing 2021

Jun 17, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2021-06-16

Reporting Person: BRAWLEY OTIS W (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$12.67	2031-04-08	Common Stock (400000)		Direct

Footnotes

F1: The shares vest in equal monthly installments over the thirty-six months following April 9, 2021. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.